Brief: Regenxbio Initiates Pivotal Phase Of Affinity Duchenne Trial Of Rgx-202 Gene Therapy
18/11/2024 12:53
Nov 18 (Reuters) - Regenxbio Inc RGNX.O :
* REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE®
TRIAL OF
RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA
* REGENXBIO INC - FAVORABLE SAFETY PROFILE OBSERVED WITH NO
SERIOUS ADVERSE EVENTS
* REGENXBIO INC - FDA ALIGNMENT ACHIEVED FOR AFFINITY
DUCHENNE
PROGRAM, BLA EXPECTED IN 2026
Source text: ID:nPn2GH8XTa
Further company coverage: RGNX.O
((Reuters.Briefs@thomsonreuters.com;))